

Income statement

	Q3 2022 £m	Q3 2022 \$m	YTD Q3 2022 £m	YTD Q3 2022 \$m
TURNOVER	7,829	9,263	21,948	27,551
Cost of sales	(2,423)	(2,845)	(7,316)	(9,184)
Gross profit	5,406	6,418	14,632	18,367
Selling, general and administration	(2,056)	(2,426)	(5,934)	(7,449)
Research and development	(1,346)	(1,596)	(3,691)	(4,633)
Royalty income	255	308	552	693
Other Operating income	(1,068)	(1,344)	(994)	(1,248)
OPERATING PROFIT	1,191	1,360	4,565	5,730
Finance income	22	27	50	63
Finance expense	(200)	(235)	(609)	(764)
Share of after tax losses of JV and associates	(1)	(1)	(4)	(5)
PROFIT BEFORE TAXATION	1,012	1,151	4,002	5,024
Taxation	(233)	(274)	(706)	(887)
PROFIT AFTER TAXATION FROM CONTINUING OPERATIONS	779	877	3,296	4,137
Profit after taxation from discontinued operations and other gains/(losses) from the demerger	2,347	2,921	2,972	3,731
Re-measurement of discontinued operations distributed to shareholders on demerger	7,227	9,072	7,227	9,072
PROFIT AFTER TAXATION FROM DISCONTINUED OPERATIONS	9,574	11,993	10,199	12,803
PROFIT AFTER TAX FOR THE PERIOD	10,353	12,870	13,495	16,940
Profit attributable to non-controlling interests from continuing operations	20	13	335	421
Profit attributable to shareholders from continuing operations	759	865	2,961	3,717
Profit attributable to non-controlling interests from discontinued operations	18	15	205	257
Profit attributable to shareholders from discontinued operations	9,556	11,977	9,994	12,545
	10,353	12,870	13,495	16,940
Profit attributable to non-controlling interests	38	28	540	678
Profit attributable to shareholders	10,315	12,842	12,955	16,262
	10,353	12,870	13,495	16,940
EARNINGS PER SHARE FROM CONTINUING OPERATIONS	18.8p	21.4c	73.6p	92.4c
EARNINGS PER SHARE FROM DISCONTINUED OPERATIONS	237.1p	297.7c	248.4p	311.8c
TOTAL EARNINGS PER SHARE	255.9p	319.1c	322.0p	404.2c
Diluted earnings per share from continuing operations	18.6p	20.7c	72.5p	91.0c
Diluted earnings per share from discontinued operations	233.7p	293.4c	244.8p	307.3c
Total diluted earnings per share	252.3p	314.1c	317.3p	398.3c

US dollar amounts shown in the income statement above are a convenience translation of the sterling amounts. US dollar results for the nine months ended 30 September 2022 are calculated using average rates for the period. US dollar results for the three months ended 30 September 2022 are calculated as the difference between these nine months results translated into US dollars and US dollar results previously published for the six months ended 30 June 2022.

US dollar amounts for the detailed sales tables below are a convenience translation of the sterling amounts. US dollar results for the nine months ended 30 September 2022 are calculated using average rates for the period. US dollar results for the three months ended 30 September 2022 are calculated as the difference between these nine months results translated into US dollars and US dollar results previously published for the six months ended 30 June 2022.

Specialty Medicines turnover – three months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	1,486	1,002	331	153	1,763	1,194	391	178
<i>Dolutegravir products</i>	1,328	876	312	140	1,572	1,043	368	161
<i>Tivicay</i>	342	227	67	48	403	270	79	54
<i>Triumeq</i>	467	325	87	55	552	387	102	63
<i>Juluca</i>	159	124	32	3	188	148	37	3
<i>Dovato</i>	360	200	126	34	429	238	150	41
<i>Rukobia</i>	21	21	1	(1)	25	25	1	(1)
<i>Cabenuva</i>	101	87	11	3	123	105	14	4
<i>Apretude</i>	10	10	-	-	12	12	-	-
Other	26	8	7	11	31	9	8	14
Oncology	164	83	70	11	195	98	84	13
<i>Zejula</i>	120	58	51	11	142	68	61	13
<i>Blenrep</i>	36	20	16	-	43	24	19	-
<i>Jemperli</i>	8	5	3	-	10	6	4	-
Immuno-inflammation, respiratory and other	688	484	96	108	816	574	113	129
<i>Benlysta</i>	308	257	21	30	366	306	24	36
<i>Nucala</i>	366	226	76	64	433	267	90	76
Other	14	1	(1)	14	17	1	(1)	17
Specialty Medicines excluding pandemic	2,338	1,569	497	272	2,774	1,866	588	320
Pandemic	411	25	3	383	445	-	(13)	458
<i>Xevudy</i>	411	25	3	383	445	-	(13)	458
Specialty Medicines	2,749	1,594	500	655	3,219	1,866	575	778

Specialty Medicines turnover – nine months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
HIV	4,071	2,593	966	512	5,110	3,255	1,213	642
<i>Dolutegravir products</i>	3,709	2,313	919	477	4,656	2,904	1,154	598
<i>Tivicay</i>	1,008	588	204	216	1,266	738	256	272
<i>Triumeq</i>	1,320	877	278	165	1,657	1,102	349	206
<i>Juluca</i>	444	339	95	10	557	426	119	12
<i>Dovato</i>	937	509	342	86	1,176	638	430	108
<i>Rukobia</i>	56	54	2	-	70	68	2	-
<i>Cabenuva</i>	211	182	25	4	265	228	32	5
<i>Apretude</i>	20	20	-	-	25	25	-	-
Other	75	24	20	31	94	30	25	39
Oncology	445	235	186	24	558	295	233	31
<i>Zejula</i>	338	172	142	24	424	216	178	30
<i>Blenrep</i>	91	55	36	-	114	69	45	-
<i>Jemperli</i>	16	8	8	-	20	10	10	-
Immuno-inflammation, respiratory and other	1,888	1,318	272	298	2,370	1,654	341	375
<i>Benlysta</i>	820	678	60	82	1,029	851	75	103
<i>Nucala</i>	1,028	639	215	174	1,290	802	270	218
Other	40	1	(3)	42	51	1	(4)	54
Specialty Medicines excluding pandemic	6,404	4,146	1,424	834	8,038	5,204	1,787	1,047
Pandemic	2,184	818	437	929	2,742	1,027	549	1,166
<i>Xevudy</i>	2,184	818	437	929	2,742	1,027	549	1,166
Specialty Medicines	8,588	4,964	1,861	1,763	10,780	6,231	2,336	2,213

Vaccines turnover – three months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Meningitis	441	281	91	69	536	344	108	84
<i>Bexsero</i>	275	166	85	24	332	203	101	28
<i>Menveo</i>	157	115	4	38	193	141	5	47
<i>Other</i>	9	-	2	7	11	-	2	9
Influenza	388	330	28	30	485	414	35	36
<i>Fluarix, FluLaval</i>	388	330	28	30	485	414	35	36
Shingles	760	475	173	112	897	556	205	136
<i>Shingrix</i>	760	475	173	112	897	556	205	136
Established Vaccines	884	380	190	314	1,051	455	225	371
<i>Infanrix, Pediarix</i>	188	116	41	31	224	139	49	36
<i>Boostrix</i>	179	122	36	21	213	146	42	25
Hepatitis	164	103	38	23	195	123	45	27
<i>Rotarix</i>	143	25	29	89	170	30	34	106
<i>Synflorix</i>	72	-	8	64	84	-	9	75
<i>Priorix, Priorix Tetra, Varilrix</i>	51	1	22	28	60	1	26	33
<i>Cervarix</i>	40	-	7	33	48	-	9	39
<i>Other</i>	47	13	9	25	57	16	11	30
Vaccines excluding pandemic	2,473	1,466	482	525	2,969	1,769	573	627
Pandemic vaccines	6	-	-	6	8	-	-	8
Pandemic adjuvant	6	-	-	6	8	-	-	8
Vaccines	2,479	1,466	482	531	2,977	1,769	573	635

Vaccines turnover – nine months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Meningitis	888	500	261	127	1,115	628	328	159
<i>Bexsero</i>	603	297	245	61	757	373	308	76
<i>Menveo</i>	268	203	12	53	337	255	15	67
<i>Other</i>	17	-	4	13	21	-	5	16
Influenza	438	332	28	78	550	417	35	98
<i>Fluarix, FluLaval</i>	438	332	28	78	550	417	35	98
Shingles	2,189	1,484	484	221	2,748	1,863	608	277
<i>Shingrix</i>	2,189	1,484	484	221	2,748	1,863	608	277
Established Vaccines	2,342	939	532	871	2,940	1,179	668	1,093
<i>Infanrix, Pediarix</i>	483	279	101	103	606	350	127	129
<i>Boostrix</i>	463	287	107	69	581	360	134	87
Hepatitis	445	279	106	60	559	351	133	75
<i>Rotarix</i>	380	74	90	216	477	93	113	271
<i>Synflorix</i>	237	-	24	213	298	-	30	268
<i>Priorix, Priorix Tetra, Varilrix</i>	138	1	73	64	173	1	92	80
<i>Cervarix</i>	91	-	15	76	114	-	19	95
<i>Other</i>	105	19	16	70	132	24	20	88
Vaccines excluding pandemic	5,857	3,255	1,305	1,297	7,353	4,087	1,639	1,627
Pandemic vaccines	6	-	-	6	8	-	-	8
Pandemic adjuvant	6	-	-	6	8	-	-	8
Vaccines	5,863	3,255	1,305	1,303	7,361	4,087	1,639	1,635

General Medicines turnover – three months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	1,682	863	329	490	1,984	1,021	386	577
<i>Arnuity Ellipta</i>	19	17	-	2	23	20	-	3
<i>Anoro Ellipta</i>	129	65	41	23	153	78	48	27
<i>Avamys/Veramyst</i>	71	-	15	56	82	-	17	65
<i>Flixotide/Flovent</i>	141	95	16	30	166	112	18	36
<i>Incruse Ellipta</i>	56	33	15	8	66	40	17	9
<i>Relvar/Breo Ellipta</i>	312	156	83	73	369	185	98	86
<i>Seretide/Advair</i>	265	58	66	141	310	67	77	166
<i>Trelegy Ellipta</i>	465	340	60	65	552	403	72	77
<i>Ventolin</i>	190	98	26	66	223	115	30	78
Other Respiratory	34	1	7	26	40	1	9	30
Other General	919	92	173	654	1,085	108	203	774
Dermatology	94	-	24	70	111	-	28	83
Augmentin	150	-	34	116	178	-	39	139
Avodart	86	-	27	59	102	-	32	70
Lamictal	132	70	27	35	156	82	31	43
Other	457	22	61	374	538	26	73	439
General Medicines	2,601	955	502	1,144	3,069	1,129	589	1,351

General Medicines turnover – nine months ended 30 September 2022

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Respiratory	4,866	2,431	1,010	1,425	6,108	3,052	1,268	1,788
<i>Arnuity Ellipta</i>	45	39	-	6	56	48	-	8
<i>Anoro Ellipta</i>	345	165	118	62	433	207	148	78
<i>Avamys/Veramyst</i>	239	-	51	188	300	-	64	236
<i>Flixotide/Flovent</i>	411	278	52	81	516	349	65	102
<i>Incruse Ellipta</i>	157	88	48	21	197	111	60	26
<i>Relvar/Breo Ellipta</i>	896	426	253	217	1,125	535	318	272
<i>Seretide/Advair</i>	829	203	212	414	1,041	255	266	520
<i>Trelegy Ellipta</i>	1,272	932	171	169	1,597	1,170	215	212
<i>Ventolin</i>	565	300	83	182	709	377	104	228
Other Respiratory	107	-	22	85	134	-	28	106
Other General	2,631	268	517	1,846	3,303	336	649	2,318
Dermatology	277	-	79	198	348	-	99	249
Augmentin	409	-	107	302	513	-	134	379
Avodart	248	-	81	167	312	-	102	210
Lamictal	379	194	80	105	476	243	100	133
Other	1,318	74	170	1,074	1,654	93	214	1,347
General Medicines	7,497	2,699	1,527	3,271	9,411	3,388	1,917	4,106

Commercial operations turnover

	Total £m	US £m	Europe £m	Inter- national £m	Total \$m	US \$m	Europe \$m	Inter- national \$m
Three months ended 30 September 2022	7,829	4,015	1,484	2,330	9,262	4,763	1,734	2,765
Nine months ended 30 September 2022	21,948	10,918	4,693	6,337	27,551	13,705	5,891	7,955

Balance sheet

	30-Sep-22 £m	30-Sep-22 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,901	9,850
Right of use assets	749	828
Goodwill	7,195	7,962
Other intangible assets	15,589	17,251
Investments in associates and joint ventures	71	79
Other investments	1,559	1,725
Deferred tax asset	4,818	5,332
Derivative financial instruments	12	13
Other non-current assets	1,170	1,295
Total non-current assets	40,064	44,335
Current assets		
Inventories	4,659	5,156
Current tax recoverable	586	648
Trade and other receivables	7,508	8,309
Derivative financial instruments	216	239
Current equity investments	3,482	3,853
Liquid investments	73	81
Cash & cash equivalents	3,606	3,990
Assets held for sale/distribution	119	132
Total current assets	20,249	22,408
TOTAL ASSETS	60,313	66,743
LIABILITIES		
Current liabilities		
Short-term borrowings	(2,793)	(3,091)
Contingent consideration liabilities	(967)	(1,070)
Trade and other payables	(16,115)	(17,832)
Derivative financial instruments	(325)	(360)
Current tax payable	(129)	(143)
Short term provisions	(624)	(691)
Total current liabilities	(20,953)	(23,187)
Non-current liabilities		
Long-term borrowings	(19,322)	(21,382)
Corporation tax payable	(218)	(241)
Deferred tax liabilities	(364)	(403)
Pension and other post-employment benefits	(2,928)	(3,240)
Other provisions	(561)	(621)
Derivative financial instruments	(1)	(1)
Contingent consideration liabilities	(6,360)	(7,038)
Other non-current liabilities	(890)	(985)
Total non-current liabilities	(30,644)	(33,911)
TOTAL LIABILITIES	(51,597)	(57,098)
NET ASSETS	8,716	9,645
EQUITY		
Share Capital	1,347	1,491
Share premium account	3,440	3,807
Retained earnings	2,592	2,868
Other reserves	1,773	1,962
Shareholders' equity	9,152	10,128
Non-controlling Interests	(436)	(483)
TOTAL EQUITY	8,716	9,645

US dollar amounts shown above are a convenience translation of the sterling amounts.